nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABL1—esophageal cancer	0.182	0.315	CbGaD
Imatinib—CA1—esophageal cancer	0.167	0.288	CbGaD
Imatinib—CA2—esophageal cancer	0.126	0.218	CbGaD
Imatinib—PTGS1—esophageal cancer	0.0693	0.12	CbGaD
Imatinib—ABCB1—esophageal cancer	0.0337	0.0583	CbGaD
Imatinib—SLC22A2—Cisplatin—esophageal cancer	0.0294	0.214	CbGbCtD
Imatinib—ABCG2—Carboplatin—esophageal cancer	0.0254	0.185	CbGbCtD
Imatinib—ABCG2—Cisplatin—esophageal cancer	0.0217	0.158	CbGbCtD
Imatinib—CYP2C9—Capecitabine—esophageal cancer	0.016	0.117	CbGbCtD
Imatinib—ABCG2—Methotrexate—esophageal cancer	0.0141	0.103	CbGbCtD
Imatinib—ALB—Methotrexate—esophageal cancer	0.00971	0.0707	CbGbCtD
Imatinib—CYP2C9—Cisplatin—esophageal cancer	0.00806	0.0587	CbGbCtD
Imatinib—ABCB1—Cisplatin—esophageal cancer	0.00782	0.057	CbGbCtD
Imatinib—CA3—pericardium—esophageal cancer	0.00589	0.102	CbGeAlD
Imatinib—ABCB1—Methotrexate—esophageal cancer	0.00508	0.037	CbGbCtD
Imatinib—CA6—exocrine gland—esophageal cancer	0.00227	0.0396	CbGeAlD
Imatinib—DDR1—bronchus—esophageal cancer	0.00157	0.0273	CbGeAlD
Imatinib—DDR1—smooth muscle tissue—esophageal cancer	0.00153	0.0267	CbGeAlD
Imatinib—DDR1—trachea—esophageal cancer	0.00141	0.0245	CbGeAlD
Imatinib—KIT—exocrine gland—esophageal cancer	0.00132	0.023	CbGeAlD
Imatinib—Ponatinib—ABL1—esophageal cancer	0.00112	0.244	CrCbGaD
Imatinib—ABCA3—lung—esophageal cancer	0.00109	0.0191	CbGeAlD
Imatinib—DDR1—lung—esophageal cancer	0.00101	0.0176	CbGeAlD
Imatinib—PIP4K2C—bronchus—esophageal cancer	0.000966	0.0168	CbGeAlD
Imatinib—Ponatinib—KDR—esophageal cancer	0.000949	0.208	CrCbGaD
Imatinib—CA7—trachea—esophageal cancer	0.000903	0.0157	CbGeAlD
Imatinib—PIP4K2C—trachea—esophageal cancer	0.000868	0.0151	CbGeAlD
Imatinib—LCK—bronchus—esophageal cancer	0.000858	0.0149	CbGeAlD
Imatinib—KIT—neck—esophageal cancer	0.000845	0.0147	CbGeAlD
Imatinib—PDGFRB—neck—esophageal cancer	0.000825	0.0144	CbGeAlD
Imatinib—Nilotinib—ABL1—esophageal cancer	0.000824	0.18	CrCbGaD
Imatinib—CA2—exocrine gland—esophageal cancer	0.000783	0.0136	CbGeAlD
Imatinib—CA7—digestive system—esophageal cancer	0.000777	0.0135	CbGeAlD
Imatinib—LCK—trachea—esophageal cancer	0.00077	0.0134	CbGeAlD
Imatinib—Nilotinib—CA1—esophageal cancer	0.000753	0.165	CrCbGaD
Imatinib—ABCA3—lymph node—esophageal cancer	0.000749	0.013	CbGeAlD
Imatinib—NQO2—bronchus—esophageal cancer	0.00071	0.0124	CbGeAlD
Imatinib—PDGFRA—smooth muscle tissue—esophageal cancer	0.000693	0.0121	CbGeAlD
Imatinib—DDR1—lymph node—esophageal cancer	0.000691	0.012	CbGeAlD
Imatinib—CA9—digestive system—esophageal cancer	0.000682	0.0119	CbGeAlD
Imatinib—ABL2—lung—esophageal cancer	0.000659	0.0115	CbGeAlD
Imatinib—NQO2—trachea—esophageal cancer	0.000637	0.0111	CbGeAlD
Imatinib—PDGFRA—trachea—esophageal cancer	0.000636	0.0111	CbGeAlD
Imatinib—PIP4K2C—lung—esophageal cancer	0.000623	0.0109	CbGeAlD
Imatinib—CSF1R—bronchus—esophageal cancer	0.000623	0.0109	CbGeAlD
Imatinib—CSF1R—smooth muscle tissue—esophageal cancer	0.00061	0.0106	CbGeAlD
Imatinib—CA3—lung—esophageal cancer	0.000595	0.0104	CbGeAlD
Imatinib—CA12—trachea—esophageal cancer	0.000587	0.0102	CbGeAlD
Imatinib—KIT—epithelium—esophageal cancer	0.000575	0.01	CbGeAlD
Imatinib—Nilotinib—CA2—esophageal cancer	0.000571	0.125	CrCbGaD
Imatinib—KIT—bronchus—esophageal cancer	0.000566	0.00985	CbGeAlD
Imatinib—PDGFRB—epithelium—esophageal cancer	0.000561	0.00977	CbGeAlD
Imatinib—CSF1R—trachea—esophageal cancer	0.00056	0.00974	CbGeAlD
Imatinib—KIT—smooth muscle tissue—esophageal cancer	0.000554	0.00964	CbGeAlD
Imatinib—LCK—lung—esophageal cancer	0.000553	0.00963	CbGeAlD
Imatinib—PDGFRB—bronchus—esophageal cancer	0.000553	0.00962	CbGeAlD
Imatinib—PDGFRA—digestive system—esophageal cancer	0.000547	0.00952	CbGeAlD
Imatinib—PDGFRB—smooth muscle tissue—esophageal cancer	0.000541	0.00942	CbGeAlD
Imatinib—SLC22A2—digestive system—esophageal cancer	0.000519	0.00904	CbGeAlD
Imatinib—KIT—trachea—esophageal cancer	0.000508	0.00885	CbGeAlD
Imatinib—CA12—digestive system—esophageal cancer	0.000505	0.00879	CbGeAlD
Imatinib—CA2—neck—esophageal cancer	0.000501	0.00872	CbGeAlD
Imatinib—PDGFRB—trachea—esophageal cancer	0.000496	0.00864	CbGeAlD
Imatinib—ABL1—bronchus—esophageal cancer	0.000493	0.00858	CbGeAlD
Imatinib—ABL1—smooth muscle tissue—esophageal cancer	0.000482	0.00839	CbGeAlD
Imatinib—CSF1R—digestive system—esophageal cancer	0.000482	0.00838	CbGeAlD
Imatinib—NQO2—lung—esophageal cancer	0.000458	0.00797	CbGeAlD
Imatinib—PDGFRA—lung—esophageal cancer	0.000457	0.00795	CbGeAlD
Imatinib—ABL2—lymph node—esophageal cancer	0.000451	0.00785	CbGeAlD
Imatinib—ABL1—trachea—esophageal cancer	0.000442	0.0077	CbGeAlD
Imatinib—SLC47A1—digestive system—esophageal cancer	0.00044	0.00766	CbGeAlD
Imatinib—KIT—digestive system—esophageal cancer	0.000437	0.00761	CbGeAlD
Imatinib—PDGFRB—digestive system—esophageal cancer	0.000427	0.00743	CbGeAlD
Imatinib—PIP4K2C—lymph node—esophageal cancer	0.000426	0.00742	CbGeAlD
Imatinib—CA12—lung—esophageal cancer	0.000422	0.00734	CbGeAlD
Imatinib—CA3—lymph node—esophageal cancer	0.000407	0.00709	CbGeAlD
Imatinib—CSF1R—lung—esophageal cancer	0.000402	0.007	CbGeAlD
Imatinib—CA1—digestive system—esophageal cancer	0.0004	0.00696	CbGeAlD
Imatinib—ABL1—digestive system—esophageal cancer	0.000381	0.00663	CbGeAlD
Imatinib—LCK—lymph node—esophageal cancer	0.000379	0.00659	CbGeAlD
Imatinib—SLC47A1—lung—esophageal cancer	0.000367	0.00639	CbGeAlD
Imatinib—KIT—lung—esophageal cancer	0.000365	0.00636	CbGeAlD
Imatinib—PDGFRB—lung—esophageal cancer	0.000357	0.00621	CbGeAlD
Imatinib—CA2—epithelium—esophageal cancer	0.000341	0.00593	CbGeAlD
Imatinib—CA2—bronchus—esophageal cancer	0.000335	0.00584	CbGeAlD
Imatinib—ORM1—lung—esophageal cancer	0.000335	0.00582	CbGeAlD
Imatinib—CA1—lung—esophageal cancer	0.000334	0.00581	CbGeAlD
Imatinib—CA2—smooth muscle tissue—esophageal cancer	0.000328	0.00571	CbGeAlD
Imatinib—ABL1—lung—esophageal cancer	0.000318	0.00553	CbGeAlD
Imatinib—NQO2—lymph node—esophageal cancer	0.000313	0.00545	CbGeAlD
Imatinib—PDGFRA—lymph node—esophageal cancer	0.000312	0.00544	CbGeAlD
Imatinib—CA2—trachea—esophageal cancer	0.000301	0.00524	CbGeAlD
Imatinib—CYP2C19—digestive system—esophageal cancer	0.000283	0.00492	CbGeAlD
Imatinib—CSF1R—lymph node—esophageal cancer	0.000275	0.00479	CbGeAlD
Imatinib—PTGS1—epithelium—esophageal cancer	0.000263	0.00458	CbGeAlD
Imatinib—CA2—digestive system—esophageal cancer	0.000259	0.00451	CbGeAlD
Imatinib—PTGS1—smooth muscle tissue—esophageal cancer	0.000254	0.00441	CbGeAlD
Imatinib—SLC47A1—lymph node—esophageal cancer	0.000251	0.00437	CbGeAlD
Imatinib—KIT—lymph node—esophageal cancer	0.00025	0.00435	CbGeAlD
Imatinib—PDGFRB—lymph node—esophageal cancer	0.000244	0.00425	CbGeAlD
Imatinib—PTGS1—trachea—esophageal cancer	0.000233	0.00405	CbGeAlD
Imatinib—CYP1A2—digestive system—esophageal cancer	0.000231	0.00402	CbGeAlD
Imatinib—ORM1—lymph node—esophageal cancer	0.000229	0.00398	CbGeAlD
Imatinib—CA1—lymph node—esophageal cancer	0.000228	0.00398	CbGeAlD
Imatinib—CYP3A5—digestive system—esophageal cancer	0.000223	0.00388	CbGeAlD
Imatinib—CYP2C9—digestive system—esophageal cancer	0.000219	0.00382	CbGeAlD
Imatinib—ABL1—lymph node—esophageal cancer	0.000217	0.00378	CbGeAlD
Imatinib—CA2—lung—esophageal cancer	0.000216	0.00377	CbGeAlD
Imatinib—Ponatinib—ABCB1—esophageal cancer	0.000206	0.0451	CrCbGaD
Imatinib—ALB—lymph node—esophageal cancer	0.000201	0.00349	CbGeAlD
Imatinib—ABCG2—lung—esophageal cancer	0.0002	0.00349	CbGeAlD
Imatinib—PTGS1—digestive system—esophageal cancer	0.0002	0.00348	CbGeAlD
Imatinib—CYP1A2—lung—esophageal cancer	0.000193	0.00336	CbGeAlD
Imatinib—CYP3A5—lung—esophageal cancer	0.000186	0.00324	CbGeAlD
Imatinib—CYP3A4—digestive system—esophageal cancer	0.000167	0.00291	CbGeAlD
Imatinib—PTGS1—lung—esophageal cancer	0.000167	0.00291	CbGeAlD
Imatinib—Cardiac disorder—Cisplatin—esophageal cancer	0.000166	0.00174	CcSEcCtD
Imatinib—Abdominal distension—Capecitabine—esophageal cancer	0.000166	0.00174	CcSEcCtD
Imatinib—Dysphagia—Capecitabine—esophageal cancer	0.000165	0.00173	CcSEcCtD
Imatinib—Influenza—Capecitabine—esophageal cancer	0.000165	0.00173	CcSEcCtD
Imatinib—CYP2D6—digestive system—esophageal cancer	0.000165	0.00286	CbGeAlD
Imatinib—Immune system disorder—Cisplatin—esophageal cancer	0.000162	0.0017	CcSEcCtD
Imatinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000161	0.00169	CcSEcCtD
Imatinib—Sweating increased—Capecitabine—esophageal cancer	0.000161	0.00168	CcSEcCtD
Imatinib—Angina pectoris—Capecitabine—esophageal cancer	0.000161	0.00168	CcSEcCtD
Imatinib—Arrhythmia—Cisplatin—esophageal cancer	0.00016	0.00168	CcSEcCtD
Imatinib—Alopecia—Cisplatin—esophageal cancer	0.000158	0.00166	CcSEcCtD
Imatinib—Hepatic failure—Methotrexate—esophageal cancer	0.000158	0.00166	CcSEcCtD
Imatinib—Pancytopenia—Capecitabine—esophageal cancer	0.000157	0.00164	CcSEcCtD
Imatinib—Erythema—Cisplatin—esophageal cancer	0.000156	0.00163	CcSEcCtD
Imatinib—Malnutrition—Cisplatin—esophageal cancer	0.000156	0.00163	CcSEcCtD
Imatinib—ABCB1—epithelium—esophageal cancer	0.000156	0.00271	CbGeAlD
Imatinib—Neutropenia—Capecitabine—esophageal cancer	0.000154	0.00162	CcSEcCtD
Imatinib—Renal failure acute—Methotrexate—esophageal cancer	0.000154	0.00161	CcSEcCtD
Imatinib—Flatulence—Cisplatin—esophageal cancer	0.000154	0.00161	CcSEcCtD
Imatinib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000153	0.00161	CcSEcCtD
Imatinib—Nilotinib—ABCB1—esophageal cancer	0.000152	0.0333	CrCbGaD
Imatinib—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00015	0.00158	CcSEcCtD
Imatinib—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00015	0.00158	CcSEcCtD
Imatinib—Weight increased—Capecitabine—esophageal cancer	0.00015	0.00157	CcSEcCtD
Imatinib—Muscle spasms—Cisplatin—esophageal cancer	0.00015	0.00157	CcSEcCtD
Imatinib—Weight decreased—Capecitabine—esophageal cancer	0.000149	0.00156	CcSEcCtD
Imatinib—Hyperglycaemia—Capecitabine—esophageal cancer	0.000149	0.00156	CcSEcCtD
Imatinib—CA2—lymph node—esophageal cancer	0.000148	0.00258	CbGeAlD
Imatinib—Pneumonia—Capecitabine—esophageal cancer	0.000148	0.00155	CcSEcCtD
Imatinib—Infestation—Capecitabine—esophageal cancer	0.000147	0.00154	CcSEcCtD
Imatinib—Infestation NOS—Capecitabine—esophageal cancer	0.000147	0.00154	CcSEcCtD
Imatinib—Vision blurred—Cisplatin—esophageal cancer	0.000147	0.00154	CcSEcCtD
Imatinib—Depression—Capecitabine—esophageal cancer	0.000147	0.00154	CcSEcCtD
Imatinib—Tremor—Cisplatin—esophageal cancer	0.000146	0.00153	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000146	0.00153	CcSEcCtD
Imatinib—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000145	0.00152	CcSEcCtD
Imatinib—Lethargy—Methotrexate—esophageal cancer	0.000145	0.00152	CcSEcCtD
Imatinib—Ill-defined disorder—Cisplatin—esophageal cancer	0.000145	0.00152	CcSEcCtD
Imatinib—Renal failure—Capecitabine—esophageal cancer	0.000144	0.00151	CcSEcCtD
Imatinib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000144	0.00151	CcSEcCtD
Imatinib—Myocardial infarction—Capecitabine—esophageal cancer	0.000144	0.00151	CcSEcCtD
Imatinib—Anaemia—Cisplatin—esophageal cancer	0.000144	0.00151	CcSEcCtD
Imatinib—Stomatitis—Capecitabine—esophageal cancer	0.000143	0.0015	CcSEcCtD
Imatinib—Jaundice—Capecitabine—esophageal cancer	0.000143	0.0015	CcSEcCtD
Imatinib—Conjunctivitis—Capecitabine—esophageal cancer	0.000143	0.0015	CcSEcCtD
Imatinib—Urinary tract infection—Capecitabine—esophageal cancer	0.000143	0.0015	CcSEcCtD
Imatinib—Malaise—Cisplatin—esophageal cancer	0.000141	0.00147	CcSEcCtD
Imatinib—Haematuria—Capecitabine—esophageal cancer	0.00014	0.00147	CcSEcCtD
Imatinib—Leukopenia—Cisplatin—esophageal cancer	0.000139	0.00146	CcSEcCtD
Imatinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000139	0.00146	CcSEcCtD
Imatinib—Epistaxis—Capecitabine—esophageal cancer	0.000139	0.00145	CcSEcCtD
Imatinib—ABCB1—trachea—esophageal cancer	0.000138	0.00239	CbGeAlD
Imatinib—Agranulocytosis—Capecitabine—esophageal cancer	0.000137	0.00144	CcSEcCtD
Imatinib—ABCG2—lymph node—esophageal cancer	0.000137	0.00239	CbGeAlD
Imatinib—Convulsion—Cisplatin—esophageal cancer	0.000135	0.00142	CcSEcCtD
Imatinib—Myalgia—Cisplatin—esophageal cancer	0.000133	0.00139	CcSEcCtD
Imatinib—Haemoglobin—Capecitabine—esophageal cancer	0.000133	0.00139	CcSEcCtD
Imatinib—Rhinitis—Capecitabine—esophageal cancer	0.000132	0.00139	CcSEcCtD
Imatinib—Anxiety—Cisplatin—esophageal cancer	0.000132	0.00139	CcSEcCtD
Imatinib—Haemorrhage—Capecitabine—esophageal cancer	0.000132	0.00138	CcSEcCtD
Imatinib—Hepatitis—Capecitabine—esophageal cancer	0.000132	0.00138	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000132	0.00138	CcSEcCtD
Imatinib—Hypoaesthesia—Capecitabine—esophageal cancer	0.000131	0.00138	CcSEcCtD
Imatinib—Discomfort—Cisplatin—esophageal cancer	0.000131	0.00137	CcSEcCtD
Imatinib—Pharyngitis—Capecitabine—esophageal cancer	0.000131	0.00137	CcSEcCtD
Imatinib—Urinary tract disorder—Capecitabine—esophageal cancer	0.00013	0.00137	CcSEcCtD
Imatinib—Oedema peripheral—Capecitabine—esophageal cancer	0.00013	0.00136	CcSEcCtD
Imatinib—Connective tissue disorder—Capecitabine—esophageal cancer	0.00013	0.00136	CcSEcCtD
Imatinib—Urethral disorder—Capecitabine—esophageal cancer	0.000129	0.00136	CcSEcCtD
Imatinib—Breast disorder—Methotrexate—esophageal cancer	0.000128	0.00135	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000128	0.00134	CcSEcCtD
Imatinib—Anaphylactic shock—Cisplatin—esophageal cancer	0.000127	0.00133	CcSEcCtD
Imatinib—Oedema—Cisplatin—esophageal cancer	0.000127	0.00133	CcSEcCtD
Imatinib—Infection—Cisplatin—esophageal cancer	0.000126	0.00132	CcSEcCtD
Imatinib—Erythema multiforme—Capecitabine—esophageal cancer	0.000125	0.00131	CcSEcCtD
Imatinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000125	0.00131	CcSEcCtD
Imatinib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000125	0.00131	CcSEcCtD
Imatinib—Tachycardia—Cisplatin—esophageal cancer	0.000124	0.0013	CcSEcCtD
Imatinib—Skin disorder—Cisplatin—esophageal cancer	0.000124	0.0013	CcSEcCtD
Imatinib—Eye disorder—Capecitabine—esophageal cancer	0.000123	0.00129	CcSEcCtD
Imatinib—Tinnitus—Capecitabine—esophageal cancer	0.000123	0.00129	CcSEcCtD
Imatinib—Hyperhidrosis—Cisplatin—esophageal cancer	0.000123	0.00129	CcSEcCtD
Imatinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000122	0.00128	CcSEcCtD
Imatinib—Flushing—Capecitabine—esophageal cancer	0.000122	0.00128	CcSEcCtD
Imatinib—Eosinophilia—Methotrexate—esophageal cancer	0.000121	0.00127	CcSEcCtD
Imatinib—Anorexia—Cisplatin—esophageal cancer	0.000121	0.00127	CcSEcCtD
Imatinib—Pancreatitis—Methotrexate—esophageal cancer	0.00012	0.00126	CcSEcCtD
Imatinib—Angiopathy—Capecitabine—esophageal cancer	0.00012	0.00126	CcSEcCtD
Imatinib—Immune system disorder—Capecitabine—esophageal cancer	0.000119	0.00125	CcSEcCtD
Imatinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000119	0.00125	CcSEcCtD
Imatinib—Hypotension—Cisplatin—esophageal cancer	0.000119	0.00125	CcSEcCtD
Imatinib—Chills—Capecitabine—esophageal cancer	0.000118	0.00124	CcSEcCtD
Imatinib—ABCB1—digestive system—esophageal cancer	0.000118	0.00206	CbGeAlD
Imatinib—Arrhythmia—Capecitabine—esophageal cancer	0.000118	0.00124	CcSEcCtD
Imatinib—Alopecia—Capecitabine—esophageal cancer	0.000117	0.00122	CcSEcCtD
Imatinib—Pancytopenia—Methotrexate—esophageal cancer	0.000117	0.00122	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000116	0.00121	CcSEcCtD
Imatinib—Mental disorder—Capecitabine—esophageal cancer	0.000116	0.00121	CcSEcCtD
Imatinib—Erythema—Capecitabine—esophageal cancer	0.000115	0.0012	CcSEcCtD
Imatinib—Malnutrition—Capecitabine—esophageal cancer	0.000115	0.0012	CcSEcCtD
Imatinib—Neutropenia—Methotrexate—esophageal cancer	0.000115	0.0012	CcSEcCtD
Imatinib—PTGS1—lymph node—esophageal cancer	0.000114	0.00199	CbGeAlD
Imatinib—Paraesthesia—Cisplatin—esophageal cancer	0.000114	0.0012	CcSEcCtD
Imatinib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000114	0.0012	CcSEcCtD
Imatinib—Dyspnoea—Cisplatin—esophageal cancer	0.000113	0.00119	CcSEcCtD
Imatinib—Flatulence—Capecitabine—esophageal cancer	0.000113	0.00119	CcSEcCtD
Imatinib—Erectile dysfunction—Methotrexate—esophageal cancer	0.000113	0.00119	CcSEcCtD
Imatinib—Dysgeusia—Capecitabine—esophageal cancer	0.000112	0.00118	CcSEcCtD
Imatinib—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000112	0.00117	CcSEcCtD
Imatinib—Back pain—Capecitabine—esophageal cancer	0.000111	0.00116	CcSEcCtD
Imatinib—Decreased appetite—Cisplatin—esophageal cancer	0.000111	0.00116	CcSEcCtD
Imatinib—Muscle spasms—Capecitabine—esophageal cancer	0.00011	0.00116	CcSEcCtD
Imatinib—Pneumonia—Methotrexate—esophageal cancer	0.00011	0.00115	CcSEcCtD
Imatinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00011	0.00115	CcSEcCtD
Imatinib—Infestation NOS—Methotrexate—esophageal cancer	0.000109	0.00115	CcSEcCtD
Imatinib—Infestation—Methotrexate—esophageal cancer	0.000109	0.00115	CcSEcCtD
Imatinib—Depression—Methotrexate—esophageal cancer	0.000109	0.00114	CcSEcCtD
Imatinib—Pain—Cisplatin—esophageal cancer	0.000109	0.00114	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000108	0.00114	CcSEcCtD
Imatinib—Vision blurred—Capecitabine—esophageal cancer	0.000108	0.00114	CcSEcCtD
Imatinib—Tremor—Capecitabine—esophageal cancer	0.000108	0.00113	CcSEcCtD
Imatinib—Renal failure—Methotrexate—esophageal cancer	0.000108	0.00113	CcSEcCtD
Imatinib—Stomatitis—Methotrexate—esophageal cancer	0.000107	0.00112	CcSEcCtD
Imatinib—Ill-defined disorder—Capecitabine—esophageal cancer	0.000107	0.00112	CcSEcCtD
Imatinib—Conjunctivitis—Methotrexate—esophageal cancer	0.000106	0.00112	CcSEcCtD
Imatinib—Anaemia—Capecitabine—esophageal cancer	0.000106	0.00111	CcSEcCtD
Imatinib—Sweating—Methotrexate—esophageal cancer	0.000105	0.0011	CcSEcCtD
Imatinib—Feeling abnormal—Cisplatin—esophageal cancer	0.000105	0.0011	CcSEcCtD
Imatinib—Haematuria—Methotrexate—esophageal cancer	0.000104	0.00109	CcSEcCtD
Imatinib—Malaise—Capecitabine—esophageal cancer	0.000104	0.00109	CcSEcCtD
Imatinib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000103	0.00109	CcSEcCtD
Imatinib—Epistaxis—Methotrexate—esophageal cancer	0.000103	0.00108	CcSEcCtD
Imatinib—Vertigo—Capecitabine—esophageal cancer	0.000103	0.00108	CcSEcCtD
Imatinib—Syncope—Capecitabine—esophageal cancer	0.000103	0.00108	CcSEcCtD
Imatinib—Leukopenia—Capecitabine—esophageal cancer	0.000103	0.00108	CcSEcCtD
Imatinib—Agranulocytosis—Methotrexate—esophageal cancer	0.000102	0.00107	CcSEcCtD
Imatinib—Palpitations—Capecitabine—esophageal cancer	0.000101	0.00106	CcSEcCtD
Imatinib—Loss of consciousness—Capecitabine—esophageal cancer	0.000101	0.00106	CcSEcCtD
Imatinib—Body temperature increased—Cisplatin—esophageal cancer	0.000101	0.00105	CcSEcCtD
Imatinib—Cough—Capecitabine—esophageal cancer	0.0001	0.00105	CcSEcCtD
Imatinib—Hypertension—Capecitabine—esophageal cancer	9.92e-05	0.00104	CcSEcCtD
Imatinib—ABCB1—lung—esophageal cancer	9.88e-05	0.00172	CbGeAlD
Imatinib—Haemoglobin—Methotrexate—esophageal cancer	9.87e-05	0.00104	CcSEcCtD
Imatinib—Haemorrhage—Methotrexate—esophageal cancer	9.82e-05	0.00103	CcSEcCtD
Imatinib—Hepatitis—Methotrexate—esophageal cancer	9.82e-05	0.00103	CcSEcCtD
Imatinib—Chest pain—Capecitabine—esophageal cancer	9.78e-05	0.00103	CcSEcCtD
Imatinib—Arthralgia—Capecitabine—esophageal cancer	9.78e-05	0.00103	CcSEcCtD
Imatinib—Myalgia—Capecitabine—esophageal cancer	9.78e-05	0.00103	CcSEcCtD
Imatinib—Pharyngitis—Methotrexate—esophageal cancer	9.75e-05	0.00102	CcSEcCtD
Imatinib—Anxiety—Capecitabine—esophageal cancer	9.74e-05	0.00102	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	9.71e-05	0.00102	CcSEcCtD
Imatinib—Urinary tract disorder—Methotrexate—esophageal cancer	9.7e-05	0.00102	CcSEcCtD
Imatinib—Discomfort—Capecitabine—esophageal cancer	9.66e-05	0.00101	CcSEcCtD
Imatinib—Urethral disorder—Methotrexate—esophageal cancer	9.63e-05	0.00101	CcSEcCtD
Imatinib—Dry mouth—Capecitabine—esophageal cancer	9.56e-05	0.001	CcSEcCtD
Imatinib—Confusional state—Capecitabine—esophageal cancer	9.45e-05	0.000991	CcSEcCtD
Imatinib—Oedema—Capecitabine—esophageal cancer	9.37e-05	0.000983	CcSEcCtD
Imatinib—Hypersensitivity—Cisplatin—esophageal cancer	9.37e-05	0.000982	CcSEcCtD
Imatinib—Infection—Capecitabine—esophageal cancer	9.31e-05	0.000977	CcSEcCtD
Imatinib—Erythema multiforme—Methotrexate—esophageal cancer	9.29e-05	0.000974	CcSEcCtD
Imatinib—Shock—Capecitabine—esophageal cancer	9.22e-05	0.000967	CcSEcCtD
Imatinib—Nervous system disorder—Capecitabine—esophageal cancer	9.19e-05	0.000964	CcSEcCtD
Imatinib—Eye disorder—Methotrexate—esophageal cancer	9.18e-05	0.000963	CcSEcCtD
Imatinib—Thrombocytopenia—Capecitabine—esophageal cancer	9.18e-05	0.000962	CcSEcCtD
Imatinib—Tinnitus—Methotrexate—esophageal cancer	9.16e-05	0.00096	CcSEcCtD
Imatinib—Tachycardia—Capecitabine—esophageal cancer	9.15e-05	0.000959	CcSEcCtD
Imatinib—Asthenia—Cisplatin—esophageal cancer	9.12e-05	0.000957	CcSEcCtD
Imatinib—Cardiac disorder—Methotrexate—esophageal cancer	9.12e-05	0.000956	CcSEcCtD
Imatinib—Skin disorder—Capecitabine—esophageal cancer	9.11e-05	0.000955	CcSEcCtD
Imatinib—Hyperhidrosis—Capecitabine—esophageal cancer	9.06e-05	0.00095	CcSEcCtD
Imatinib—Anorexia—Capecitabine—esophageal cancer	8.94e-05	0.000937	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—esophageal cancer	8.91e-05	0.000934	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—esophageal cancer	8.87e-05	0.00093	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—esophageal cancer	8.85e-05	0.000928	CcSEcCtD
Imatinib—Chills—Methotrexate—esophageal cancer	8.81e-05	0.000924	CcSEcCtD
Imatinib—Hypotension—Capecitabine—esophageal cancer	8.76e-05	0.000918	CcSEcCtD
Imatinib—Diarrhoea—Cisplatin—esophageal cancer	8.7e-05	0.000912	CcSEcCtD
Imatinib—Alopecia—Methotrexate—esophageal cancer	8.68e-05	0.00091	CcSEcCtD
Imatinib—Mental disorder—Methotrexate—esophageal cancer	8.6e-05	0.000902	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—esophageal cancer	8.55e-05	0.000897	CcSEcCtD
Imatinib—Erythema—Methotrexate—esophageal cancer	8.55e-05	0.000897	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	8.54e-05	0.000896	CcSEcCtD
Imatinib—Insomnia—Capecitabine—esophageal cancer	8.48e-05	0.000889	CcSEcCtD
Imatinib—Paraesthesia—Capecitabine—esophageal cancer	8.42e-05	0.000883	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—esophageal cancer	8.37e-05	0.000878	CcSEcCtD
Imatinib—Dyspnoea—Capecitabine—esophageal cancer	8.36e-05	0.000876	CcSEcCtD
Imatinib—Back pain—Methotrexate—esophageal cancer	8.27e-05	0.000867	CcSEcCtD
Imatinib—Dyspepsia—Capecitabine—esophageal cancer	8.25e-05	0.000865	CcSEcCtD
Imatinib—Decreased appetite—Capecitabine—esophageal cancer	8.15e-05	0.000854	CcSEcCtD
Imatinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	8.09e-05	0.000849	CcSEcCtD
Imatinib—Vomiting—Cisplatin—esophageal cancer	8.09e-05	0.000848	CcSEcCtD
Imatinib—Fatigue—Capecitabine—esophageal cancer	8.08e-05	0.000847	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—esophageal cancer	8.06e-05	0.000845	CcSEcCtD
Imatinib—Rash—Cisplatin—esophageal cancer	8.02e-05	0.000841	CcSEcCtD
Imatinib—Pain—Capecitabine—esophageal cancer	8.02e-05	0.000841	CcSEcCtD
Imatinib—Constipation—Capecitabine—esophageal cancer	8.02e-05	0.000841	CcSEcCtD
Imatinib—Dermatitis—Cisplatin—esophageal cancer	8.01e-05	0.00084	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—esophageal cancer	7.93e-05	0.000832	CcSEcCtD
Imatinib—Anaemia—Methotrexate—esophageal cancer	7.9e-05	0.000829	CcSEcCtD
Imatinib—Feeling abnormal—Capecitabine—esophageal cancer	7.72e-05	0.00081	CcSEcCtD
Imatinib—Malaise—Methotrexate—esophageal cancer	7.71e-05	0.000809	CcSEcCtD
Imatinib—Vertigo—Methotrexate—esophageal cancer	7.68e-05	0.000806	CcSEcCtD
Imatinib—Gastrointestinal pain—Capecitabine—esophageal cancer	7.67e-05	0.000804	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—esophageal cancer	7.65e-05	0.000803	CcSEcCtD
Imatinib—Nausea—Cisplatin—esophageal cancer	7.55e-05	0.000792	CcSEcCtD
Imatinib—Cough—Methotrexate—esophageal cancer	7.46e-05	0.000782	CcSEcCtD
Imatinib—Urticaria—Capecitabine—esophageal cancer	7.45e-05	0.000781	CcSEcCtD
Imatinib—Abdominal pain—Capecitabine—esophageal cancer	7.41e-05	0.000777	CcSEcCtD
Imatinib—Body temperature increased—Capecitabine—esophageal cancer	7.41e-05	0.000777	CcSEcCtD
Imatinib—Convulsion—Methotrexate—esophageal cancer	7.41e-05	0.000777	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—esophageal cancer	7.28e-05	0.000763	CcSEcCtD
Imatinib—Chest pain—Methotrexate—esophageal cancer	7.28e-05	0.000763	CcSEcCtD
Imatinib—Myalgia—Methotrexate—esophageal cancer	7.28e-05	0.000763	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	7.23e-05	0.000758	CcSEcCtD
Imatinib—Discomfort—Methotrexate—esophageal cancer	7.19e-05	0.000754	CcSEcCtD
Imatinib—Confusional state—Methotrexate—esophageal cancer	7.04e-05	0.000738	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—esophageal cancer	6.98e-05	0.000732	CcSEcCtD
Imatinib—Infection—Methotrexate—esophageal cancer	6.93e-05	0.000727	CcSEcCtD
Imatinib—Hypersensitivity—Capecitabine—esophageal cancer	6.91e-05	0.000724	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—esophageal cancer	6.84e-05	0.000718	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—esophageal cancer	6.83e-05	0.000716	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—esophageal cancer	6.78e-05	0.000711	CcSEcCtD
Imatinib—ABCB1—lymph node—esophageal cancer	6.76e-05	0.00118	CbGeAlD
Imatinib—Hyperhidrosis—Methotrexate—esophageal cancer	6.75e-05	0.000707	CcSEcCtD
Imatinib—Asthenia—Capecitabine—esophageal cancer	6.73e-05	0.000705	CcSEcCtD
Imatinib—Anorexia—Methotrexate—esophageal cancer	6.65e-05	0.000697	CcSEcCtD
Imatinib—Pruritus—Capecitabine—esophageal cancer	6.63e-05	0.000695	CcSEcCtD
Imatinib—Hypotension—Methotrexate—esophageal cancer	6.52e-05	0.000684	CcSEcCtD
Imatinib—Diarrhoea—Capecitabine—esophageal cancer	6.41e-05	0.000673	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	6.36e-05	0.000667	CcSEcCtD
Imatinib—Insomnia—Methotrexate—esophageal cancer	6.31e-05	0.000662	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—esophageal cancer	6.27e-05	0.000657	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—esophageal cancer	6.22e-05	0.000652	CcSEcCtD
Imatinib—Somnolence—Methotrexate—esophageal cancer	6.2e-05	0.000651	CcSEcCtD
Imatinib—Dizziness—Capecitabine—esophageal cancer	6.2e-05	0.00065	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—esophageal cancer	6.14e-05	0.000644	CcSEcCtD
Imatinib—Decreased appetite—Methotrexate—esophageal cancer	6.07e-05	0.000636	CcSEcCtD
Imatinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	6.02e-05	0.000632	CcSEcCtD
Imatinib—Fatigue—Methotrexate—esophageal cancer	6.02e-05	0.000631	CcSEcCtD
Imatinib—Pain—Methotrexate—esophageal cancer	5.97e-05	0.000626	CcSEcCtD
Imatinib—Vomiting—Capecitabine—esophageal cancer	5.96e-05	0.000625	CcSEcCtD
Imatinib—Rash—Capecitabine—esophageal cancer	5.91e-05	0.00062	CcSEcCtD
Imatinib—Dermatitis—Capecitabine—esophageal cancer	5.9e-05	0.000619	CcSEcCtD
Imatinib—Headache—Capecitabine—esophageal cancer	5.87e-05	0.000616	CcSEcCtD
Imatinib—Feeling abnormal—Methotrexate—esophageal cancer	5.75e-05	0.000603	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—esophageal cancer	5.71e-05	0.000598	CcSEcCtD
Imatinib—Nausea—Capecitabine—esophageal cancer	5.57e-05	0.000584	CcSEcCtD
Imatinib—Urticaria—Methotrexate—esophageal cancer	5.54e-05	0.000581	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—esophageal cancer	5.52e-05	0.000578	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—esophageal cancer	5.52e-05	0.000578	CcSEcCtD
Imatinib—Hypersensitivity—Methotrexate—esophageal cancer	5.14e-05	0.000539	CcSEcCtD
Imatinib—Asthenia—Methotrexate—esophageal cancer	5.01e-05	0.000525	CcSEcCtD
Imatinib—Pruritus—Methotrexate—esophageal cancer	4.94e-05	0.000518	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—esophageal cancer	4.77e-05	0.000501	CcSEcCtD
Imatinib—Dizziness—Methotrexate—esophageal cancer	4.61e-05	0.000484	CcSEcCtD
Imatinib—Vomiting—Methotrexate—esophageal cancer	4.44e-05	0.000465	CcSEcCtD
Imatinib—Rash—Methotrexate—esophageal cancer	4.4e-05	0.000461	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—esophageal cancer	4.4e-05	0.000461	CcSEcCtD
Imatinib—Headache—Methotrexate—esophageal cancer	4.37e-05	0.000458	CcSEcCtD
Imatinib—Nausea—Methotrexate—esophageal cancer	4.14e-05	0.000435	CcSEcCtD
Imatinib—PDGFRB—Immune System—CDKN1A—esophageal cancer	3.06e-06	2.4e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NOTCH1—esophageal cancer	3.05e-06	2.39e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS1—esophageal cancer	3.04e-06	2.38e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ENO1—esophageal cancer	3.04e-06	2.38e-05	CbGpPWpGaD
Imatinib—CA2—Metabolism—PIK3CA—esophageal cancer	3.04e-06	2.38e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EP300—esophageal cancer	3.01e-06	2.36e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GAPDH—esophageal cancer	3.01e-06	2.36e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PSME2—esophageal cancer	3e-06	2.35e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PSME1—esophageal cancer	3e-06	2.35e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.98e-06	2.34e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EP300—esophageal cancer	2.98e-06	2.34e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CRABP1—esophageal cancer	2.98e-06	2.34e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—CDKN1A—esophageal cancer	2.98e-06	2.34e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ENO1—esophageal cancer	2.97e-06	2.33e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS1—esophageal cancer	2.97e-06	2.33e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—PIK3CA—esophageal cancer	2.97e-06	2.32e-05	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.97e-06	2.32e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTT1—esophageal cancer	2.96e-06	2.32e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—BCL2—esophageal cancer	2.96e-06	2.32e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.95e-06	2.31e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP2A6—esophageal cancer	2.92e-06	2.29e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PSME1—esophageal cancer	2.92e-06	2.29e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PSME2—esophageal cancer	2.92e-06	2.29e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.91e-06	2.28e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.91e-06	2.28e-05	CbGpPWpGaD
Imatinib—CA1—Metabolism—PIK3CA—esophageal cancer	2.91e-06	2.28e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.91e-06	2.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EP300—esophageal cancer	2.91e-06	2.28e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—EGFR—esophageal cancer	2.91e-06	2.28e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NOS3—esophageal cancer	2.9e-06	2.27e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP1B1—esophageal cancer	2.88e-06	2.26e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—ERBB2—esophageal cancer	2.87e-06	2.25e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—HMOX1—esophageal cancer	2.87e-06	2.25e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—PIK3CA—esophageal cancer	2.85e-06	2.23e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNG7—esophageal cancer	2.84e-06	2.22e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EP300—esophageal cancer	2.84e-06	2.22e-05	CbGpPWpGaD
Imatinib—LCK—Disease—NOS3—esophageal cancer	2.83e-06	2.22e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CDKN1A—esophageal cancer	2.82e-06	2.21e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ENO1—esophageal cancer	2.8e-06	2.19e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.8e-06	2.19e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.79e-06	2.19e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TYMP—esophageal cancer	2.78e-06	2.18e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS1—esophageal cancer	2.77e-06	2.17e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ENO1—esophageal cancer	2.77e-06	2.17e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CREBBP—esophageal cancer	2.76e-06	2.17e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PSME2—esophageal cancer	2.76e-06	2.16e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PSME1—esophageal cancer	2.76e-06	2.16e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ABCB1—esophageal cancer	2.75e-06	2.16e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EGFR—esophageal cancer	2.75e-06	2.16e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NOS3—esophageal cancer	2.75e-06	2.15e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MYC—esophageal cancer	2.75e-06	2.15e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PSME1—esophageal cancer	2.73e-06	2.14e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PSME2—esophageal cancer	2.73e-06	2.14e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HIF1A—esophageal cancer	2.71e-06	2.13e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ERBB2—esophageal cancer	2.71e-06	2.13e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP19A1—esophageal cancer	2.71e-06	2.12e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.71e-06	2.12e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EP300—esophageal cancer	2.69e-06	2.11e-05	CbGpPWpGaD
Imatinib—KIT—Disease—EGFR—esophageal cancer	2.69e-06	2.1e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—EP300—esophageal cancer	2.66e-06	2.09e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALDH2—esophageal cancer	2.66e-06	2.08e-05	CbGpPWpGaD
Imatinib—LCK—Disease—ERBB2—esophageal cancer	2.65e-06	2.08e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.64e-06	2.07e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—esophageal cancer	2.62e-06	2.06e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.62e-06	2.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—esophageal cancer	2.6e-06	2.04e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KDR—esophageal cancer	2.6e-06	2.03e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—esophageal cancer	2.59e-06	2.03e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP1B1—esophageal cancer	2.59e-06	2.03e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CREBBP—esophageal cancer	2.57e-06	2.01e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB2—esophageal cancer	2.57e-06	2.01e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—esophageal cancer	2.57e-06	2.01e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—PIK3CA—esophageal cancer	2.56e-06	2.01e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CREBBP—esophageal cancer	2.55e-06	2e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CREBBP—esophageal cancer	2.54e-06	1.99e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—esophageal cancer	2.54e-06	1.99e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTT1—esophageal cancer	2.53e-06	1.98e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—PIK3CA—esophageal cancer	2.52e-06	1.98e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.52e-06	1.98e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.52e-06	1.97e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TPI1—esophageal cancer	2.52e-06	1.97e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP2A6—esophageal cancer	2.5e-06	1.96e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.49e-06	1.95e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—esophageal cancer	2.48e-06	1.94e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NOS3—esophageal cancer	2.47e-06	1.94e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—HMOX1—esophageal cancer	2.47e-06	1.94e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CREBBP—esophageal cancer	2.47e-06	1.93e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CDKN1A—esophageal cancer	2.45e-06	1.92e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	2.45e-06	1.92e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP19A1—esophageal cancer	2.43e-06	1.9e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.42e-06	1.9e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—esophageal cancer	2.42e-06	1.89e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.41e-06	1.89e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCND1—esophageal cancer	2.4e-06	1.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—PIK3CA—esophageal cancer	2.39e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.39e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.38e-06	1.86e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.37e-06	1.86e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ABCB1—esophageal cancer	2.37e-06	1.86e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CREBBP—esophageal cancer	2.37e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS1—esophageal cancer	2.37e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ENO1—esophageal cancer	2.37e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1B1—esophageal cancer	2.36e-06	1.85e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—esophageal cancer	2.34e-06	1.83e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EP300—esophageal cancer	2.34e-06	1.83e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PSME2—esophageal cancer	2.33e-06	1.83e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PSME1—esophageal cancer	2.33e-06	1.83e-05	CbGpPWpGaD
Imatinib—KIT—Disease—PIK3CA—esophageal cancer	2.33e-06	1.83e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.32e-06	1.82e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CDKN1A—esophageal cancer	2.32e-06	1.82e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—esophageal cancer	2.31e-06	1.81e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.3e-06	1.8e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—NOS3—esophageal cancer	2.3e-06	1.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—esophageal cancer	2.29e-06	1.79e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—NOS3—esophageal cancer	2.28e-06	1.79e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—NOS3—esophageal cancer	2.28e-06	1.78e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—esophageal cancer	2.27e-06	1.78e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CDKN1A—esophageal cancer	2.27e-06	1.78e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.24e-06	1.75e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—esophageal cancer	2.23e-06	1.75e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HMOX1—esophageal cancer	2.22e-06	1.74e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CREBBP—esophageal cancer	2.22e-06	1.74e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP19A1—esophageal cancer	2.22e-06	1.74e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—NOS3—esophageal cancer	2.21e-06	1.73e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EP300—esophageal cancer	2.21e-06	1.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—esophageal cancer	2.21e-06	1.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN1A—esophageal cancer	2.2e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNG7—esophageal cancer	2.19e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.18e-06	1.71e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HMOX1—esophageal cancer	2.16e-06	1.7e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EP300—esophageal cancer	2.16e-06	1.69e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—esophageal cancer	2.15e-06	1.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—esophageal cancer	2.15e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ABCB1—esophageal cancer	2.13e-06	1.67e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—NOS3—esophageal cancer	2.12e-06	1.66e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—esophageal cancer	2.1e-06	1.65e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—esophageal cancer	2.1e-06	1.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EP300—esophageal cancer	2.09e-06	1.64e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—esophageal cancer	2.08e-06	1.63e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—esophageal cancer	2.08e-06	1.63e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.05e-06	1.61e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—esophageal cancer	2.04e-06	1.6e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HMOX1—esophageal cancer	2.04e-06	1.6e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.04e-06	1.6e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HMOX1—esophageal cancer	2.02e-06	1.58e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—esophageal cancer	2.02e-06	1.58e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1B1—esophageal cancer	2.01e-06	1.58e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—esophageal cancer	1.99e-06	1.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—esophageal cancer	1.99e-06	1.56e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOS3—esophageal cancer	1.99e-06	1.56e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.98e-06	1.55e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1A—esophageal cancer	1.98e-06	1.55e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—esophageal cancer	1.97e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.96e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.95e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.94e-06	1.52e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—esophageal cancer	1.94e-06	1.52e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.93e-06	1.51e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—esophageal cancer	1.92e-06	1.51e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—esophageal cancer	1.91e-06	1.49e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.89e-06	1.48e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EP300—esophageal cancer	1.88e-06	1.47e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—esophageal cancer	1.88e-06	1.47e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—esophageal cancer	1.88e-06	1.47e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—esophageal cancer	1.86e-06	1.46e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.84e-06	1.44e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—esophageal cancer	1.84e-06	1.44e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.83e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.83e-06	1.43e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—esophageal cancer	1.82e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PSME2—esophageal cancer	1.8e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PSME1—esophageal cancer	1.8e-06	1.41e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.79e-06	1.41e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—esophageal cancer	1.78e-06	1.4e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—EP300—esophageal cancer	1.75e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—EP300—esophageal cancer	1.73e-06	1.36e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—EP300—esophageal cancer	1.73e-06	1.36e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.73e-06	1.35e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—esophageal cancer	1.73e-06	1.35e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.7e-06	1.33e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—EP300—esophageal cancer	1.68e-06	1.32e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.66e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NOS3—esophageal cancer	1.65e-06	1.29e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—esophageal cancer	1.64e-06	1.29e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—esophageal cancer	1.64e-06	1.28e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—esophageal cancer	1.63e-06	1.28e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—EP300—esophageal cancer	1.61e-06	1.26e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.61e-06	1.26e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—esophageal cancer	1.6e-06	1.26e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—esophageal cancer	1.6e-06	1.25e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	1.59e-06	1.24e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CREBBP—esophageal cancer	1.59e-06	1.24e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—esophageal cancer	1.58e-06	1.24e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.55e-06	1.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—esophageal cancer	1.55e-06	1.21e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EP300—esophageal cancer	1.51e-06	1.18e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.51e-06	1.18e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—esophageal cancer	1.49e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.47e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.46e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.42e-06	1.12e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—NOS3—esophageal cancer	1.42e-06	1.11e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—esophageal cancer	1.39e-06	1.09e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CREBBP—esophageal cancer	1.39e-06	1.09e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—esophageal cancer	1.35e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.33e-06	1.05e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—esophageal cancer	1.32e-06	1.03e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.31e-06	1.03e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—esophageal cancer	1.3e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.3e-06	1.02e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.29e-06	1.01e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—esophageal cancer	1.29e-06	1.01e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—esophageal cancer	1.28e-06	1.01e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—esophageal cancer	1.28e-06	1e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.28e-06	1e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NOS3—esophageal cancer	1.27e-06	9.98e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.25e-06	9.83e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—EP300—esophageal cancer	1.25e-06	9.82e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NOS3—esophageal cancer	1.24e-06	9.74e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—esophageal cancer	1.24e-06	9.74e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—esophageal cancer	1.19e-06	9.35e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NOS3—esophageal cancer	1.17e-06	9.18e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.17e-06	9.13e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NOS3—esophageal cancer	1.16e-06	9.1e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—esophageal cancer	1.14e-06	8.91e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	1.12e-06	8.75e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.11e-06	8.69e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—esophageal cancer	1.08e-06	8.47e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—EP300—esophageal cancer	1.08e-06	8.46e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.07e-06	8.4e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.06e-06	8.33e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NOS3—esophageal cancer	9.93e-07	7.78e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—EP300—esophageal cancer	9.69e-07	7.59e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—EP300—esophageal cancer	9.46e-07	7.41e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—esophageal cancer	9.27e-07	7.27e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—esophageal cancer	9.08e-07	7.11e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—EP300—esophageal cancer	8.91e-07	6.98e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—EP300—esophageal cancer	8.84e-07	6.92e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	8.56e-07	6.71e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—esophageal cancer	7.99e-07	6.26e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NOS3—esophageal cancer	7.66e-07	6e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—EP300—esophageal cancer	7.55e-07	5.92e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—esophageal cancer	7.17e-07	5.62e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	7.01e-07	5.49e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	7e-07	5.48e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	6.59e-07	5.17e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—esophageal cancer	6.54e-07	5.12e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—EP300—esophageal cancer	5.83e-07	4.57e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—esophageal cancer	5.59e-07	4.38e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	4.31e-07	3.38e-06	CbGpPWpGaD
